Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
about
Platinum-induced hearing loss after treatment for childhood cancerHearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood CancerThe effect of amifostine on differentiation of the human megakaryoblastic Dami cell line.Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing lossTreatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study.SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastomaFactors affecting survival of medulloblastoma in children: the changing concept of management.Ototoxicity and cancer therapy.The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies.Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies.Protein Synthesis Inhibition and Activation of the c-Jun N-Terminal Kinase Are Potential Contributors to Cisplatin Ototoxicity.Acquired sensorineural hearing loss in children: current research and therapeutic perspectives.Progress in the Development of Preventative Drugs for Cisplatin-Induced Hearing Loss.Ototoxicity: A Challenge in Diagnosis and Treatment.
P2860
Q26470526-9BACED8C-1570-4D5E-8118-6CE841064E54Q30368168-A8DBB480-16CC-4EF8-8B66-51E0E0444F23Q33432515-EB028442-1396-435C-83A1-663E36C5CBCEQ35172741-9E778FAA-9BAA-47A7-83E0-F77FCF4B011FQ36253772-0CE85312-A481-4C30-970F-3B713D6B9945Q36358551-70B4D93B-FB11-4710-8B05-7D92F028C736Q38583250-06E00260-F4DF-4919-BB5C-0C1CD5FDA06BQ38727368-A7E36DA0-73FD-4F6E-A4D0-171BC36640C1Q38739253-9F3B9C4F-BF71-4EE4-8C99-4040A11177ACQ38964704-F4274648-A195-4FBD-82A7-5BA05E77D45DQ42361422-CCBCE887-AEBF-4693-9FCB-330AF7D179E7Q42369948-3E8B4A8A-33D2-4E31-8E94-3E44FF0D9558Q47554578-42CEE18E-D440-41C5-A510-94F116ED75F1Q47716828-10D38B12-8A3D-454D-A61C-85151201EE14Q50300972-04F512E4-C8C1-498F-884E-F431DD506013
P2860
Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@ast
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@en
type
label
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@ast
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@en
prefLabel
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@ast
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@en
P2093
P2860
P50
P356
P1433
P1476
Evaluation of amifostine for p ...... or high-risk medulloblastoma.
@en
P2093
Amar Gajjar
Arzu Onar-Thomas
Atmaram Pai Panandiker
Clinton F Stewart
Cynthia Wetmore
Gregory T Armstrong
Ibrahim Qaddoumi
James G Gurney
John A Heath
P2860
P304
P356
10.1093/NEUONC/NOT241
P50
P577
2014-01-10T00:00:00Z